Item 8.01 Other Events.
On June 15, 2021, the Company issued a press release providing additional
details from the VISION-1 Phase 3 clinical study of its proprietary pilocarpine
formulation, MicroLine, for the treatment of presbyopia. The press release also
announces a PDUFA target action date for MydCombi, a proprietary microdose
formulation for in-office pupil dilation. Furthermore, the press release
announces licensing agreements with a potential to earn up to $100 million in
development milestones over the next four years, as well as significant sales
royalties. A copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
99.1 Press Release of the Company, dated June 15, 2021.
© Edgar Online, source Glimpses